In the XTJYF group, 21 subjects dropped out (17.1%); in the placebo group, 23 did (18.9%, P = 0.74). The primary reasons cited for dropout in the XTJYF and placebo groups, respectively, were AE (4.9% versus 4.1%; P = 1); lost to Patients with a score reduction of at least 30% from the baseline SCL-90-R GSI score were classified as "much improved," and 50%, as "very much improved." * XTJYF versus placebo, P < 0.05.